News Releases

Press Releases

  • 7/26/16 7:00 am EDT

    -Common Stock (Nasdaq:PAVM) and Warrants (Nasdaq:PAVMW) will trade separately-

    -Units (Nasdaq:PAVMU) will cease trading upon separation-

    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq:PAVMU), a highly differentiated, multi-product medical device company, announced today that the common stock and warrants underlying the units sold in its initial public offering would commence separate trading on or about July 27, 2016. The common stock and warrants will be listed on the Nasdaq Capital Market (“Nasdaq”) under the symbols PAVM and PAVMW, respectively. The units, which are currently trading on Nasdaq under themore...
  • 7/14/16 7:00 am EDT

    -Commercialization of PortIO™ implantable vascular access device anticipated in 2017-

    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq:PAVMU), a highly differentiated, multi-product medical device company, announced today that it has set a Q4 2016 timeline for FDA 510(k) submission of its first product, the PortIO™ implantable vascular access device. PortIO has entered verification and validation testing, the final phase of pre-submission testing. Lishan Aklog, M.D., Chairman and CEO of PAVmed, said “We are excited about our timeline for submittingmore...
  • 6/22/16 7:00 am EDT

    - Device designed to revolutionize treatment of Carpal Tunnel Syndrome -

    - Completely percutaneous procedure would replace invasive surgery -

    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq:PAVMU), an innovative multi-product medical device company, today announced the successful completion of a pre-clinical human cadaver study, demonstrating that the Company’s completely percutaneous CarpX™ device reliably and effectively transects the ligament which causes Carpal Tunnel Syndrome (CTS). Lishan Aklog, M.D., Chairman and CEO of PAVmed, said “We are excited to report that CarpX performed very well in thismore...
  • 5/26/16 4:05 pm EDT
    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq:PAVMU), an innovative, multi-product medical device company developing and commercializing a diversified pipeline of innovative products utilizing a groundbreaking business model focused on capital efficiency and speed to market, today announced that Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer, will present at the 2016 Marcum MicroCap Conference on Thursday, June 2, 2016, at 3:30pm ET taking place in Newmore...
  • 5/13/16 9:03 pm EDT
    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq:PAVMU), a multi-product medical device company organized to conceive, develop and commercialize a diversified pipeline of innovative products, today announced results for the first quarter, ended March 31, 2016. “During the quarter, we made considerable progress on our five lead products and many other corporate objectives. This culminated with us completing our Initial Public Offering (“IPO”) this past Aprilmore...
  • 4/28/16 2:00 pm EDT

    - Units to Begin Trading Today on Nasdaq Under the Ticker Symbol “PAVMU”-

    NEW YORK--(BUSINESS WIRE)--PAVmed Inc. announced today that it has completed its initial public offering of 1,060,000 units. Each unit consists of one share of common stock and one warrant. The units were sold at an offering price of $5.00 per unit, generating gross proceeds of $5.3 million. The units will begin trading today on the Nasdaq Capital Market under the ticker symbol “PAVMU”. Once the securities comprising the units begin separate trading, the common stock andmore...

SEC Filings

Click Here to view PAVmed's SEC filings

INVESTOR PRESENTATION

Click Here to view PAVmed’s current Investor Presentation

PROXY MATERIALS

Click Here to view the Proxy Statement for PAVmed Inc 2017 Annual Meeting

Click Here view the Annual Report for PAVmed Inc 2017 Annual Meeting